Business Context and Reporting Period
Company: Aclaris Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: June 5, 2019
Event: Regulation FD Disclosure regarding a company overview presentation at the Jefferies 2019 Global Healthcare Conference.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report serves solely to announce a corporate presentation and does not contain financial statements or operational data.
Material Changes
No material changes to financial performance or operations are reported in this document. The filing is procedural, notifying the market of an upcoming investor presentation.
Guidance, Outlook, and Management Commentary
- Event Details: Management presented a company overview on June 5, 2019, at 3:30 PM ET at the Grand Hyatt Hotel in New York, New York.
- Materials: A slide presentation was provided as Exhibit 99.1.
- Legal Disclaimer: The information in the presentation is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
- Company Status: The registrant is an emerging growth company and has elected not to use the extended transition period for complying with new or revised financial accounting standards.
Investor Verification Checklist
- Review Exhibit 99.1 (Company Presentation) for specific strategic updates or clinical data not detailed in the 8-K text.
- Verify the company's emerging growth company status and its election regarding accounting standard transition periods.
- Confirm the trading symbol (ACRS) and exchange (Nasdaq) for current market data.